Today's news in laymen's terms, my interpretation as below
The ASX announcement on 1 May 2024 from OncoSil Medical Limited details the results of a groundbreaking clinical study involving their treatment device, OncoSil™, used in combination with chemotherapy for treating pancreatic cancer.
In simple terms, this study explored how OncoSil™, when added to standard chemotherapy, affects pancreatic tumors. Notably, it focused on "vascularity," which refers to the blood vessel network within the tumor.
Increasing vascularity means that the tumor has more blood vessels, which can be beneficial because chemotherapy drugs are carried through the bloodstream. More blood vessels in the tumor can lead to higher concentrations of these drugs directly in the tumor area, potentially making the treatment more effective.
The key findings from the study were:
Increased Vascularity: The use of OncoSil™ significantly increased the number of blood vessels in the tumors. This was the first time such an effect had been observed in humans, indicating a breakthrough in the approach to treating this kind of cancer.
Shrinkage of Tumors: Along with increased vascularity, there was a notable decrease in the size of the tumors, showing that the treatment was effective in reducing tumor mass.
Enhanced Treatment Outcomes: The study indicated that the increased vascularity allowed for higher concentrations of chemotherapy in the tumor, which enhances the effectiveness of the treatment.
This study marks an important step forward, as pancreatic cancer tumors typically have poor vascularity, making them difficult to treat with standard chemotherapy alone. The OncoSil™ device not only delivers a targeted, high dose of radiation directly to the tumor, reducing the risk to surrounding healthy tissues, but also improves the tumor's blood supply, enhancing the overall treatment effectiveness.
Here you go - Do your own research and consult your own medical expert to ensure this interpretation is in fact correct.
- Forums
- ASX - By Stock
- Ann: 1st Study in Man Increases Pancreatic Tumor Vascularity
Today's news in laymen's terms, my interpretation as belowThe...
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.001(6.67%) |
Mkt cap ! $35.79M |
Open | High | Low | Value | Volume |
0.8¢ | 0.9¢ | 0.8¢ | $135.0K | 16.89M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
65 | 28847611 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 500000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
65 | 28847611 | 0.007 |
24 | 9659399 | 0.006 |
18 | 15830198 | 0.005 |
9 | 9262824 | 0.004 |
2 | 2839966 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 500000 | 1 |
0.009 | 10737751 | 12 |
0.010 | 13113723 | 14 |
0.011 | 9139301 | 17 |
0.012 | 7560752 | 5 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online